Lumen Partners With UK's top PT Harry Jameson to Raise Awareness on Metabolic Health
Lumen, the creators of the world's first metabolism measurement device through the breath, have teamed up with the UK's top personal trainer, Harry Jameson, to raise awareness on metabolic health for March Metabolism Awareness Month.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005629/en/
Lumen metabolism tracking device and personalised nutrition (Photo: Lumen)
Harry is available for expert commentary on training to improve your metabolism.
"Having the ability to move between energy sources (fat and carbohydrates) is extremely important. It is a measure of your metabolic health and I’ve been working hard over the past two months to improve mine.
Using Lumen to track whether my diet, fasting or even training is pushing my metabolism in the right direction has been both fascinating from a coaches perspective and incredibly insightful from a user/customer perspective. I love how lumen keeps me both accountable and consistent with my behaviours and getting personalised nutrition plans really helps take a mental load off my shoulders in my busy schedule," says personal trainer Jameson.
Lumen and Jameson are also working together to emphasise the importance of metabolic health in combating metabolic syndrome. In the UK, 1 in 3 adults over the age of 50 will suffer from metabolic disease which is a combination of diabetes, high blood pressure (hypertension) and obesity.
The power to move away from metabolic disease by training your metabolism to switch efficiently between carbs and fats as a fuel source is a term called metabolic flexibility.
"If we feed and train our metabolism, we can process our food more efficiently - you may be able to eat a slice of pie and use it for energy faster if you have a good metabolism. We are merely training our body to use fuel sources properly- an innate mechanism. There's really no need to crash diet , if we take care of our metabolism everything else follows", says PHD in nutrition and founder of Lumen, Michal Mor.
According to research data obtained by 1 million metabolism measurements through the Lumen device, users are able to:
- Lose an average of 0.5 kg or 1.5 pounds of weight per week on a consistent basis
- Improve their metabolic flexibility by 66%
- Improve fasting windows to 12 hours daily
- Increase their daily movement by 1000 steps
Research also (Calcada et al, Gormsen et al) finds that metabolic flexibility has a profound role in assessing a person's long-term health. People with good metabolic flexibility:
- Are at lower risk of developing obesity, diabetes and metabolic disorders.
- Are in a better position to gain muscle and perform better during workouts;
- Find it easier to lose weight and maintain it
Lumen is the only device in the world to measure your metabolism through the breath and track your metabolic health to prevent diseases born out of poor nutrition.
Based on the traditional RER test which was once available only in hospitals or clinics, is accessible to anyone and anywhere for the first time-revolutionizing the way we approach weight loss, fitness and healthy nutrition decision making.
Through the co2 in your breath, Lumen measures your metabolism and provides an insight into whether you're burning fats or carbs in less than a minute.
Scientific Validation
Lumen can provide numerous insights about the metabolism of an individual, as well as valuable scientific data to increase knowledge of metabolic flexibility and nutrition. In a study conducted by San Francisco State University, Lumen has been validated to meet the gold standard for metabolic measurement.
Availability
The Lumen device is available at Lumen.me, currently priced at £299.
The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.
For media: images, video and fact sheet can be found in the press kit here.
About Lumen
Lumen helps people improve their health and fitness through technology on the forefront of personalized nutrition and metabolism. Conceived and designed by twin sisters, physiology PhDs and Ironman winners, Lumen harnesses the power of our breath to measure metabolism, which is closely linked to weight, fitness and personal health. The Lumen device measures metabolism in a single breath, in less than a minute, which previously was only possible through an hour-long lab test. Available at Lumen.me, Lumen devices ship globally, with the app available on the Apple App Store and Google Play. Lumen is headquartered in Israel, with offices in the United States.
[1] Sources: The role of low-grade inflammation and metabolic flexibility in aging and nutritional modulation thereof: A systems biology approach. Available via: https://www.sciencedirect.com/science/article/pii/S0047637414000050. Last accessed 5 May 2020.
[2] Source: Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women. Available via:https://eje.bioscientifica.com/view/journals/eje/167/4/543.xml
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005629/en/
Contact information
Media contact: Kyla Blumenfeld, press@lumen.me
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Adds González-Paullada Domínguez in Monterrey, Mexico7.1.2026 16:30:00 EET | Press release
Andersen Global broadens its Latin American platform through a Collaboration Agreement with Monterrey-based law firm González-Paullada Domínguez (GPD), further strengthening the organization’s coverage in Mexico. Founded in 2021, GPD offers comprehensive services across transactional and litigation matters. The firm advises clients across sectors—including manufacturing, real estate, insurance, information technology, mining, and banking—on corporate law, mergers and acquisitions, real estate transactions, foreign investment, commercial contracts, regulatory compliance, and ongoing legal audits. GPD also represents clients in complex civil and commercial litigation, arbitration, and insolvency proceedings. “Monterrey is a major economic hub where local credibility and deep relationships are essential, particularly for foreign investors seeking to enter the market,” said Alfonso González-Paullada Guerrero, founder and managing partner of GPD. “By collaborating with Andersen Global, we s
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 15:15:00 EET | Press release
1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new intelligent data program called 1NCE Insights. The program is part of the company’s goal of fusing AI + IoT intelligence to drive game-changing results in supply chains, smart cities, utilities and beyond. Customer-collected data is theirs and theirs alone. But with Insights, 1NCE opens access to its anonymized, networkwide data. Customers can benchmark their IoT projects a
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 15:00:00 EET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
